Research tagged [rheumatology]

Antifibrotic Therapy in Progressive Rheumatoid Arthritis-Associated Interstitial Lung Disease with a Usual Interstitial Pneumonia Pattern: Expert Perspectives on Treatment Selection and Monitoring

Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) represents a significant cause of morbidity and mortality in patients with rheumatoid arthritis, particularly when presenting with a usual interstitial pneumonia (UIP) pattern and demonstrating progressive fibrosing characteristics. This paper synthesizes expert opinions from a clinical Q&A discussion regarding the management of a 58-year-old female with progressive RA-ILD (UIP pattern) despite immunosuppression. The primary clinical dilemma revolves around the selection between nintedanib and pirfenidone, the continuation of background immunosuppression, and optimal monitoring strategies. Expert consensus favored nintedanib as a first-line antifibrotic due to robust evidence from the INBUILD trial, particularly within the UIP subgroup. However, an alternative perspective highlighted pirfenidone's potential anti-inflammatory properties and institutional experience in connective tissue disease-associated ILD. Both experts strongly advocated for the continuation of mycophenolate, citing the potential for subclinical inflammation and the risks of disease flare or acceleration upon withdrawal. A comprehensive monitoring protocol incorporating FVC, 6-minute walk distance, patient-reported outcomes, and advanced techniques like home spirometry was recommended. This synthesis underscores the complexities of managing progressive RA-ILD, emphasizing evidence-based antifibrotic selection, judicious immunosuppression, and multi-modal monitoring to optimize patient outcomes.